This website is intended for journalists outside the US/UK/Canada, who are interested in media information from Boehringer Ingelheim.
The First global, head-to-head trial comparing second- and rst-generation EGFR-directed therapies (afatinib* and getinib respectively) in the rst-line treatment of patients with EGFR mutation-positive NSCLC
*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name XOVOLTIB® for use in patients withdistinct types of EGFR mutation-positive NSCLC. Afatinib is under regulatory review by health authorities in other countries worldwide. Registration conditions differ internationally, please refer to locally approved prescribing information.